Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...

Celý popis

Podrobná bibliografia

Vydané v:	Oncoimmunology Ročník 12; číslo 1; s. 2201147
Hlavní autori:	Blomberg, Olga S., Kos, Kevin, Spagnuolo, Lorenzo, Isaeva, Olga I., Garner, Hannah, Wellenstein, Max D., Bakker, Noor, Duits, Danique E.M., Kersten, Kelly, Klarenbeek, Sjoerd, Hau, Cheei-Sing, Kaldenbach, Daphne, Raeven, Elisabeth A.M., Vrijland, Kim, Kok, Marleen, de Visser, Karin E.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Taylor & Francis 31.12.2023 Taylor & Francis Group
Predmet:	Breast cancer metastasis myeloid cells neoadjuvant immune checkpoint blockade Original Research regulatory T cells resistance mechanisms
ISSN:	2162-402X, 2162-4011, 2162-402X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!